[go: up one dir, main page]

FR3108502B1 - Dérivés de nicotinamide mononucléotides dans le traitement et la prévention des infections bactériennes - Google Patents

Dérivés de nicotinamide mononucléotides dans le traitement et la prévention des infections bactériennes Download PDF

Info

Publication number
FR3108502B1
FR3108502B1 FR2003085A FR2003085A FR3108502B1 FR 3108502 B1 FR3108502 B1 FR 3108502B1 FR 2003085 A FR2003085 A FR 2003085A FR 2003085 A FR2003085 A FR 2003085A FR 3108502 B1 FR3108502 B1 FR 3108502B1
Authority
FR
France
Prior art keywords
prevention
treatment
bacterial infections
nicotinamide mononucleotide
mononucleotide derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2003085A
Other languages
English (en)
Other versions
FR3108502A1 (fr
Inventor
Guillaume Bermond
Laurent Garçon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvamid SA
Original Assignee
Nuvamid SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2003085A priority Critical patent/FR3108502B1/fr
Application filed by Nuvamid SA filed Critical Nuvamid SA
Priority to JP2022558101A priority patent/JP2023526726A/ja
Priority to CN202180033681.XA priority patent/CN115697349A/zh
Priority to AU2021245030A priority patent/AU2021245030A1/en
Priority to US17/914,576 priority patent/US20230210881A1/en
Priority to EP21713440.2A priority patent/EP4125929A1/fr
Priority to PCT/EP2021/057938 priority patent/WO2021191422A1/fr
Priority to CA3171744A priority patent/CA3171744A1/fr
Publication of FR3108502A1 publication Critical patent/FR3108502A1/fr
Application granted granted Critical
Publication of FR3108502B1 publication Critical patent/FR3108502B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

DÉRIVÉS DE NICOTINAMIDE MONONUCLÉOTIDES DANS LE TRAITEMENT ET LA PRÉVENTION DES INFECTIONS BACTÉRIENNES La présente invention concerne un composé de formule (I) ou un sel et/ou solvate pharmaceutiquement acceptable de celui-ci ; (I) dans lequel X, R1, R2, R3, R4, R5, R6, R7, R8, Y, et sont tels que décrits dans les revendications, pour son utilisation dans le traitement et/ou la prévention des infections bactériennes.
FR2003085A 2020-03-27 2020-03-27 Dérivés de nicotinamide mononucléotides dans le traitement et la prévention des infections bactériennes Active FR3108502B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR2003085A FR3108502B1 (fr) 2020-03-27 2020-03-27 Dérivés de nicotinamide mononucléotides dans le traitement et la prévention des infections bactériennes
CN202180033681.XA CN115697349A (zh) 2020-03-27 2021-03-26 用于治疗细菌感染的烟酰胺单核苷酸衍生物
AU2021245030A AU2021245030A1 (en) 2020-03-27 2021-03-26 Nicotinamide mononucleotide derivatives for the treatment of bacterial infections
US17/914,576 US20230210881A1 (en) 2020-03-27 2021-03-26 Nicotinamide mononucleotide derivatives for the treatment of bacterial infections
JP2022558101A JP2023526726A (ja) 2020-03-27 2021-03-26 細菌性感染症の処置のためのニコチンアミドモノヌクレオチド誘導体
EP21713440.2A EP4125929A1 (fr) 2020-03-27 2021-03-26 Dérivés de nicotinamide mononucléotides pour le traitement des infections bactériennes
PCT/EP2021/057938 WO2021191422A1 (fr) 2020-03-27 2021-03-26 Dérivés de nicotinamide mononucléotides pour le traitement des infections bactériennes
CA3171744A CA3171744A1 (fr) 2020-03-27 2021-03-26 Derives de nicotinamide mononucleotides pour le traitement des infections bacteriennes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2003085A FR3108502B1 (fr) 2020-03-27 2020-03-27 Dérivés de nicotinamide mononucléotides dans le traitement et la prévention des infections bactériennes
FR2003085 2020-03-27

Publications (2)

Publication Number Publication Date
FR3108502A1 FR3108502A1 (fr) 2021-10-01
FR3108502B1 true FR3108502B1 (fr) 2022-09-23

Family

ID=70614296

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2003085A Active FR3108502B1 (fr) 2020-03-27 2020-03-27 Dérivés de nicotinamide mononucléotides dans le traitement et la prévention des infections bactériennes

Country Status (8)

Country Link
US (1) US20230210881A1 (fr)
EP (1) EP4125929A1 (fr)
JP (1) JP2023526726A (fr)
CN (1) CN115697349A (fr)
AU (1) AU2021245030A1 (fr)
CA (1) CA3171744A1 (fr)
FR (1) FR3108502B1 (fr)
WO (1) WO2021191422A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022129490A1 (fr) * 2020-12-18 2022-06-23 Nuvamid Sa Dérivés de nicotinamide mononucléotide et utilisation associée dans le traitement et la prévention d'un dérèglement des globules rouges

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150265642A1 (en) * 2012-10-09 2015-09-24 President And Fellows Of Harvard College Nad biosynthesis and precursors in the prevention and treatment of inflammation
CN107531738B (zh) * 2015-03-16 2021-02-19 可劳迈戴斯有限公司 烟酸核苷或烟酰胺核苷组合物、其还原衍生物及其用途
KR20220137150A (ko) * 2016-04-14 2022-10-11 크로마덱스 아이엔씨. 유아용 조제유에서의 니코틴아미드 리보시드, 니코틴산 리보시드, 니코틴아미드 모노뉴클레오티드 및 니코티노일 화합물 유도체의 용도
WO2018236814A2 (fr) * 2017-06-19 2018-12-27 Gangadhara Ganapati Dérivés de nicotinamide riboside et leurs utilisations
CN109674808A (zh) * 2019-01-30 2019-04-26 四川大学 β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途
CN114423439B (zh) * 2019-09-09 2024-12-31 努瓦米德股份有限公司 Nmn用于预防和/或治疗疼痛的用途及相应组合物
CN110548040A (zh) * 2019-10-17 2019-12-10 苏州大学 β-NMN在制备脓毒症器官损伤的治疗、预防药物中的应用

Also Published As

Publication number Publication date
JP2023526726A (ja) 2023-06-23
AU2021245030A1 (en) 2022-11-03
CN115697349A (zh) 2023-02-03
US20230210881A1 (en) 2023-07-06
CA3171744A1 (fr) 2021-09-30
EP4125929A1 (fr) 2023-02-08
WO2021191422A1 (fr) 2021-09-30
FR3108502A1 (fr) 2021-10-01

Similar Documents

Publication Publication Date Title
MA54327B1 (fr) Inhibiteurs de kras g12c
MA46038A (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
MA32231B1 (fr) Composés organiques
EA202190342A1 (ru) Гетеробициклические соединения для ингибирования активности shp2
FR3107897B1 (fr) Dérivés de nicotinamide mononucléotides
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
EA202190116A1 (ru) Агент для профилактики или лечения спинальной мышечной атрофии
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
MA31419B1 (fr) Derives de pyridine
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
TNSN07022A1 (fr) Derives de pyridine
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA29926B1 (fr) Derives de pyrazine
BRPI0518760A2 (pt) sal de potÁssio do composto, e, composiÇço farmacÊutica
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
MA56526B1 (fr) Dérivés de pyrido [2,3-d] pyrimidine en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
MA49127B1 (fr) Dérivés d'indole n-substitués
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MX2020000576A (es) Compuestos quimicos.
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20211001

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5